Get started
Author

Mayuri Shende

Observed name: Prof. Mayuri Shende
ORCID: 0000-0002-5095-7295
Observed ORCID: 0000-0002-5095-7295
OpenAlex ID: A5089402878
MYCN -Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis
2021 · Konstantinos V. Floros, JinYang Cai, et al. · Cancer Research · 152
PDF
Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2021 · Daniel A.R. Heisey, Sheeba Jacob, et al. · Molecular Cancer Therapeutics · 18
PDF
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma
2025 · Konstantinos V. Floros, Carter K. Fairchild, et al. · Nature Communications · 12
PDF
Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models
2022 · Sheeba Jacob, Tia H Turner, et al. · PNAS Nexus · 11
Smart Traffic Optimization System for Emergency Vehicle Priority Based on SUMO and TraCI
2026 · Prof. Mayuri Shende, Akshata Titarmare, et al. · Zenodo (CERN European Organization for Nuclear Research)
Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma
2024 · Konstantinos V. Floros, Carter K. Fairchild, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Supplementary Figures from Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer
2023 · James D. Hampton, Erica J. Peterson, et al.
Supplementary Figures from Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer
2023 · James D. Hampton, Erica J. Peterson, et al.
Data from Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer
2023 · James D. Hampton, Erica J. Peterson, et al.
Data from Exploitation of Sulfated Glycosaminoglycan Status for Precision Medicine of Triplatin in Triple-Negative Breast Cancer
2023 · James D. Hampton, Erica J. Peterson, et al.
Supplementary table 3 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Figure S5 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Data from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Figure S2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Supplementary table 2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Figure S1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
PDF
Figure S3 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Figure S7 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
PDF
Supplementary table 1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Data from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Supplementary table 1 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Figure S4 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
PDF
Supplementary table 2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Supplementary table 3 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
Figure S2 from Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma
2023 · Daniel A.R. Heisey, Sheeba Jacob, et al.
PDF
Works count: 50
Citation count: 193
H-index: 4
I10-index: 4
Year
Topic
Type